If you are interested in exploring partnership opportunities with Sutro, contact us at



In October, 2014, Sutro announced a multi-year strategic collaboration and option to acquire agreement to design and develop novel multi-specific antibodies and antibody drug conjugates (ADCs).  This new agreement follows the December 2012 collaboration and focuses on the field of immuno-oncology, while furthering broadening the Sutro platform for discovery, development and manufacture of best-in-class biotherapetuics.


In September, 2014, Sutro announced a $300M+ collaboration with EMD Serono to discover and develop novel antibody drug conjugates for several targets in the field of oncology.  Sutro is responsible for identifying lead molecules and producing both preclinical and clinical material using its Xpress CF+™ platform.